3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Glioma
8
Glioblastoma
7
Recurrence
3
Osteosarcoma
3
Neuroblastoma
3
Medulloblastoma
3
Ependymoma
3
Central Nervous System Neoplasms
3
Wilms Tumor
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Cholangiocarcinoma
2
Brain Neoplasms
2
Xanthogranuloma, Juvenile
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Neuroendocrine Tumors
1
Meningioma
1
Histiocytic Sarcoma
1
Gliosarcoma
1
Familial ependymoma
1
Esthesioneuroblastoma, Olfactory
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
16
Hydroxyurea
7
Everolimus
7
Bevacizumab
7
lutetium Lu 177 dotatate
6
gallium Ga 68 dotatate
6
Radiosurgery
6
Proton Therapy
6
Specimen Handling
5
pembrolizumab
4
Surveys and Questionnaires
4
Surgical Procedures, Operative
4
Radiotherapy
4
Imatinib Mesylate
4
Cyclophosphamide
4
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
4
aldesleukin
3
abemaciclib
3
Tranexamic Acid
3
Temozolomide
3
Sunitinib
3
Sodium Chloride
3
Radiotherapy, Intensity-Modulated
3
Observation
3
Nivolumab
3
Ga(III)-DOTATOC
3
90Y-octreotide, DOTA-Tyr(3)-
3
vistusertib
2
trametinib
2
ribociclib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningioma
×
olaparib
×
CNS
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled